FDA approves first eye drops to treat age-related vision loss

https://img.etimg.com/thumb/width-420,height-315,imgsize-15578,resizemode-75,msid-123170411/news/international/us/ditch-your-glasses-breakthrough-eye-drops-approved-by-fda-to-fix-your-near-vision-instantly.jpg

The FDA has approved VIZZ, the first aceclidine-based eye drops to treat presbyopia, offering a non-surgical alternative to reading glasses for age-related near vision loss.

• VIZZ works by creating a “pinhole effect” through pupil constriction, improving near vision within 30 minutes with effects lasting up to 10 hours from a single daily dose.

• Clinical trials involving hundreds of participants over 30,000 treatment days showed no serious side effects, with the drops proving more tolerable than previous treatments like Vuity.

• The condition affects over 128 million adults in the United States and nearly two billion people worldwide, representing a massive market for this breakthrough treatment.

• LENZ Therapeutics expects to begin distributing samples to eye care professionals by October 2025, with full commercial availability by the fourth quarter of 2025.

Why it matters

This represents the first major breakthrough in treating presbyopia pharmacologically, offering millions of aging adults a convenient alternative to reading glasses and potentially transforming how age-related vision loss is managed globally.

Comments

Popular posts from this blog

Jawahar Navodaya Vidayalaya (JNV) School

The Best Foldable Phones of 2025: A Comprehensive Comparison

THINGS TO BE NEEDED WHEN TRAVELING IN EUROPE